@FierceMedDev: Myriad slaps Quest with BRCA cancer test patent suit. Article | Follow @FierceMedDev
@MarkHFierce: Stryker paid $13.2M to settle SEC bribery charges but doesn't admit or deny any wrongdoing. Story | Follow @MarkHFierce
@MichaelGFierce: This week's Chutes & Ladders from FierceBiotech: Eli Lilly's board elects multinational financial leader, and more. Item | Follow @MichaelGFierce
> LabCorp ($LH) will start selling Qiagen's new companion diagnostic for colorectal cancer patients, which is designed to spot patients best suited for Eli Lilly's ($LLY) Erbitux drug treatment. Item
> ACell, a Maryland company developing surgical and wound-management products, has begun expanding its manufacturing facility in Lafayette, IN. Item
> Henry Ford Hospital in Detroit and Windsor Regional Hospital in Ontario, Canada, are developing plans to join forces on medical device research and testing. Story
> Danish device company R82 A/S faces an FDA warning letter addressing quality system violations in products such as its Cougar, Panther and Cheetah wheelchairs, as well as its Rabbit-brand mobile standing frame. Letter
> Beckman Coulter obtained a CE mark for a new, enhanced vitamin D assay. Item
> Are cardiac stents overused? An essay in The New Yorker explores the issue. Blog
Biotech News
@FierceBiotech: J&J wins FDA panel blessing for hepatitis C blockbuster hopeful. Story | Follow @FierceBiotech
@JohnCFierce: Let's see. Friday. Today Gilead's team will take its bows at the sofosbuvir panel. Then a vote and break for celebratory drinks, pictures. | Follow @JohnCFierce
@DamianFierce: Aerie prices $67M IPO and becomes 40th biotech to go public this year. More | Follow @DamianFierce
@EmilyMFierce: When is a medical treatment unnecessary? Article | Follow @EmilyMFierce
> Public Citizen goes on a witch hunt at the FDA. Editor's corner
> Versant Ventures amassing $200M fund for biotech upstarts. More
> Alexion bags another FDA 'breakthrough' for rare-disease drug. Story
Pharma News
@FiercePharma: ICYMI: GSK saves $431M moving retirees to private healthcare exchanges. Story | Follow @FiercePharma
@EricPFierce: South Africa's Aspen Pharmacare is a major generic drugmaker poised to get bigger. Article | Follow @EricPFierce
@CarlyHFierce: ICYMI: With Aptalis sale a no-go, TPG plots IPO instead. More | Follow @CarlyHFierce
> Celgene raises earnings forecast third time. More
> FDA again finds itself playing role as pain med police. Story
> Japan's frustrated Eisai loses fight with DEA. Article